{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:36:00Z","timestamp":1793496960628,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":280,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100476","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T17:45:57Z","timestamp":1634060757000},"page":"100476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Supportive care in multiple myeloma: Current practices and advances"],"prefix":"10.1016","volume":"29","author":[{"given":"Teresa S.","family":"Miceli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100476_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2021.100476_bib0002","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0003","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100476_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2021.100476_bib0005","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ctarc.2021.100476_bib0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2021.100476_bib0008","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2021.100476_bib0009","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma aredia study group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0011","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0012","first-page":"175","article-title":"Safety of pamidronate in patients with renal failure and hypercalcemia","volume":"45","author":"Machado","year":"1996","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2021.100476_bib0014","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2021.100476_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0016","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0017","doi-asserted-by":"crossref","first-page":"e20649","DOI":"10.1200\/jco.2014.32.15_suppl.e20649","article-title":"The evaluation of denosumab safety in patients with chronic kidney disease: an open-label study","volume":"32","author":"Block","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.ctarc.2021.100476_bib0019","series-title":"Bisphosphonate Related Jaw Osteonecrosis","author":"Gupta","year":"2021"},{"key":"10.1016\/j.ctarc.2021.100476_bib0020","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/j.oooo.2012.01.046","article-title":"Review of current literature and implications of RANKL inhibitors for oral health care providers","volume":"116","author":"Epstein","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0021","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0022","first-page":"21","article-title":"Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients","volume":"98","author":"Fourney","year":"2003","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ctarc.2021.100476_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","article-title":"A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures","volume":"361","author":"Buchbinder","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0024","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa0900563","article-title":"A randomized trial of vertebroplasty for osteoporotic spinal fractures","volume":"361","author":"Kallmes","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0026","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0027","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0028","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2021.100476_bib0029","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ctarc.2021.100476_bib0030","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom medical research council trials between 1980 and 2002\u2013medical research council adult leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0031","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0032","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100476_bib0033","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0034","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0035","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100476_bib0036","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2141.1995.tb08447.x","article-title":"Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma","volume":"89","author":"Musto","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0037","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0038","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/tid.12424","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.ctarc.2021.100476_bib0039","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2021.100476_bib0040","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/bjh.16874","article-title":"Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy","volume":"190","author":"Cook","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0041","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the international myeloma society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0042","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0043","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, streptococcus pneumoniae and haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0044","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.3324\/haematol.2014.116772","article-title":"Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma","volume":"100","author":"Hahn","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ctarc.2021.100476_bib0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2021.100476_bib0046","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European myeloma network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100476_bib0047","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1703228","article-title":"Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines","volume":"28","author":"Nordoy","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ctarc.2021.100476_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100476_bib0049","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100476_bib0051","doi-asserted-by":"crossref","unstructured":"Piedra K., Peterson T., Tan C., et\u00a0al.,: Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br. J. Haematol., 2021.","DOI":"10.1111\/bjh.17772"},{"key":"10.1016\/j.ctarc.2021.100476_bib0052","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0053","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0054","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100476_bib0055","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0056","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0057","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mayocp.2013.03.006","article-title":"The new oral anticoagulants in clinical practice","volume":"88","author":"Gonsalves","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2021.100476_bib0058","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0059","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2019-124403","article-title":"VTe rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis","volume":"134","author":"Piedra","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0060","doi-asserted-by":"crossref","first-page":"e19531","DOI":"10.1200\/jco.2015.33.15_suppl.e19531","article-title":"Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0061","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ctarc.2021.100476_bib0062","first-page":"421","article-title":"Bortezomib-induced painful neuropathy in patients with multiple myeloma","volume":"17","author":"Bilinska","year":"2013","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"10.1016\/j.ctarc.2021.100476_bib0063","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.3324\/haematol.2014.118182","article-title":"Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study","volume":"100","author":"Moreau","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ctarc.2021.100476_bib0064","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100476_bib0066","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0067","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2021.100476_bib0068","first-page":"943","article-title":"Pilot evaluation of scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy","volume":"23","author":"Pachman","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0069","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/15360288.2013.847519","article-title":"A trial of scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy","volume":"27","author":"Coyne","year":"2013","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"10.1016\/j.ctarc.2021.100476_bib0070","first-page":"1183","article-title":"Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial","volume":"28","author":"Loprinzi","year":"2020","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2021.100476_bib0071","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/1534735414534729","article-title":"A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma","volume":"13","author":"Bao","year":"2014","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.ctarc.2021.100476_bib0072","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1534735418788667","article-title":"Acupuncture for bortezomib-induced peripheral neuropathy: not just for pain","volume":"17","author":"Zhi","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.ctarc.2021.100476_bib0073","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.142.10.1298","article-title":"Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma","volume":"142","author":"Sviggum","year":"2006","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0074","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1080\/10428194.2019.1627537","article-title":"Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center","volume":"60","author":"Yau","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ctarc.2021.100476_bib0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.12925","article-title":"Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma","volume":"167","author":"Lee","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0076","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","article-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","volume":"124","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100476_bib0077","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0078","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1188\/17.CJON.S5.7-18","article-title":"Distress, fatigue, and sexuality: understanding and treating concerns and symptoms in patients with multiple myeloma","volume":"21","author":"Catamero","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ctarc.2021.100476_bib0079","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jgo.2020.11.003","article-title":"Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation","volume":"12","author":"M\u00f6ller","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.ctarc.2021.100476_bib0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ctarc.2021.100476_bib0081","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:33Z","timestamp":1762842213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":81,"alternative-id":["S2468294221001726"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100476","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supportive care in multiple myeloma: Current practices and advances","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100476"}}